专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US5912236A Broad-spectrum tumor suppressor genes gene products and methods for tumor suppressor gene therapy 失效
标题翻译：广谱肿瘤抑制基因基因产物及肿瘤抑制基因治疗方法
公开(公告)号：US5912236A
公开(公告)日：1999-06-15
申请号：US470091
申请日：1995-06-06
申请人： Hong-Ji Xu , Shi-Xue Hu , William F. Benedict
发明人： Hong-Ji Xu , Shi-Xue Hu , William F. Benedict
IPC分类号： C12N15/09 , A61K31/70 , A61K38/00 , A61K48/00 , A61P35/00 , C07H21/04 , C07K14/47 , C12N5/10 , C12P21/02 , A01N43/04 , A61N63/00
CPC分类号： A61K31/70 , C07K14/4736 , A61K38/00 , A61K48/00
摘要： The present invention relates to a broad-spectrum tumor suppressor gene and the protein expressed by that gene in appropriate host cells. The protein is a second in-frame AUG codon-initiated retinoblasoma protein of about 94 kD relative molecular mass. The present invention also relates to methods of treating a mammal having a disease or disorder characterized by abnormal cellular proliferation, such as a tumor or cancer and methods of treating abnormally proliferating cells, such as tumor or cancer cells. Treatment is accomplished by inserting a host cell compatible p94.sup.RB expression vector or an effective amount of p94.sup.RB protein into a cell or cells in need of treatment.
摘要翻译：本发明涉及广谱肿瘤抑制基因和由该基因在合适的宿主细胞中表达的蛋白质。该蛋白质是第二个具有约94kD相对分子量的框内AUG密码子起始的视网膜母细胞瘤蛋白。本发明还涉及治疗以异常细胞增殖为特征的疾病或病症如肿瘤或癌症的哺乳动物的治疗方法以及治疗异常增殖细胞如肿瘤或癌细胞的方法。通过将宿主细胞相容的p94RB表达载体或有效量的p94RB蛋白插入到需要治疗的细胞或细胞中来完成治疗。

32. 发明授权

US5853988A Diagnosis of retinoblastoma 失效
标题翻译：视网膜母细胞瘤诊断
公开(公告)号：US5853988A
公开(公告)日：1998-12-29
申请号：US958290
申请日：1992-10-08
申请人： Thaddeus P. Dryja , Stephen Friend , David W. Yandell
发明人： Thaddeus P. Dryja , Stephen Friend , David W. Yandell
IPC分类号： C07K14/47 , C12Q1/68 , C07H21/02 , C07H21/04
CPC分类号： C07K14/4736 , C12Q1/6886 , C12Q2600/156
摘要： This invention relates to nucleic acid, or fragments thereof, encoding the retinoblastoma polypeptide, the retinoblastoma polypeptide itself, methods of detecting a defective retinoblastoma gene in human patients, and methods of treating these patients.
摘要翻译：本发明涉及编码视网膜母细胞瘤多肽的核酸或其片段，视网膜母细胞瘤多肽本身，检测人类患者视网膜母细胞瘤缺陷基因的方法，以及治疗这些患者的方法。

33. 发明授权

US5759803A Recombinant retinoblastoma-associated protein 1 (E2F-1) polypeptides and cDNA 失效
标题翻译：重组视网膜母细胞瘤相关蛋白1（E2F-1）多肽和cDNA
公开(公告)号：US5759803A
公开(公告)日：1998-06-02
申请号：US882711
申请日：1992-05-13
申请人： William G. Kaelin, Jr. , Erik Flemington , William Sellers , David M. Livingston
发明人： William G. Kaelin, Jr. , Erik Flemington , William Sellers , David M. Livingston
IPC分类号： C07K14/47 , C07K16/18 , C12N15/12 , C07K14/435
CPC分类号： C07K14/4736 , C07K16/18
摘要： We have discovered a nuclear protein in normal human cells, "retinoblastoma-associated protein 1" ("RBAP-1"), also known as E2F-1, that binds directly to the retinoblastoma protein pocket of the underphosphorylated form of the retinoblastoma protein ("RB") and does not bind to phosphorylated RB or to RB with inactivating mutations. The translated RBAP-1 sequence does not resemble other proteins whose sequences are known, and RBAP-1 does not contain a sequence homologous to the transforming element common to viral proteins that bind to the RB pocket. RBAP-1 and the E2F transcription activity have similar DNA-binding specificities and can bind to at least some of the same proteins, such as RB and E4.
摘要翻译：我们已经在正常人细胞中发现了一种核因子，即“视网膜母细胞瘤相关蛋白1”（“RBAP-1”），也称为E2F-1，其直接结合视网膜母细胞瘤蛋白质的未磷酸化形式的视网膜母细胞瘤蛋白质口袋 “RB”），并且不与磷酸化的RB或具有失活突变的RB结合。翻译的RBAP-1序列不像其已知序列的其他蛋白质，并且RBAP-1不含有与结合RB袋的病毒蛋白共有的转化元件同源的序列。 RBAP-1和E2F转录活性具有相似的DNA结合特异性并且可以结合至少一些相同的蛋白质，例如RB和E4。

34. 发明申请

US20160298121A1 TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT 有权
标题翻译：核基因输出的目标完成
公开(公告)号：US20160298121A1
公开(公告)日：2016-10-13
申请号：US14874420
申请日：2015-10-03
申请人： Cold Spring Harbor Laboratory
发明人： Adrian Krainer , Isabel Aznarez
IPC分类号： C12N15/113 , C12Q1/68
CPC分类号： C12N15/1137 , C07K14/47 , C07K14/4702 , C07K14/4736 , C07K14/805 , C12N15/111 , C12N15/113 , C12N2310/11 , C12N2310/315 , C12N2310/3341 , C12N2320/11 , C12N2320/33 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , C12Y101/01205 , C12Y304/24087 , C12N2310/321 , C12N2310/3521
摘要： Provided herein are methods and compositions for increasing production of a target protein or functional RNA by a cell.
摘要翻译：本文提供了用于增加细胞产生靶蛋白或功能性RNA的方法和组合物。

35. 发明申请

US20140030319A1 Antagonists Of The Oncongenic Activity Of The Protein MDM2, And Use Thereof In the Treatment of Cancers 审中-公开
标题翻译：蛋白质MDM2的泛素化活性的拮抗剂及其在癌症治疗中的应用
公开(公告)号：US20140030319A1
公开(公告)日：2014-01-30
申请号：US13835524
申请日：2013-03-15
申请人： BRUNO TOCQUE , BOHDAN WASLYK , MARIE-CHRISTINE DUBS-POTERSZMAN
发明人： BRUNO TOCQUE , BOHDAN WASLYK , MARIE-CHRISTINE DUBS-POTERSZMAN
IPC分类号： C07K16/40 , C12N15/113
CPC分类号： C07K16/40 , A61K38/00 , C07K14/4705 , C07K14/4736 , C07K14/82 , C07K16/00 , C07K16/32 , C12N15/1137 , C12N2799/021 , C12N2799/022 , C12N2799/027
摘要： The present invention relates to the utilization of a compound capable of antagonizing at least partially the oncogenic activity of the protein Mdm2 for the preparation of a pharmaceutical composition intended more particularly to a treatment of cancers with no p53 context. It further relates to the viral vector comprising a nucleic acid sequence coding for a compound capable of inhibiting at least partially the oncogenic activity of the protein Mdm2, and to a corresponding pharmaceutical composition.
摘要翻译：本发明涉及能够至少部分地拮抗蛋白质Mdm2的致癌活性的化合物用于制备药物组合物的药物组合物的用途，更具体地说是治疗无p53上下文的癌症。它还涉及包含编码能够至少部分地抑制蛋白Mdm2的致癌活性的化合物的核酸序列的病毒载体和相应的药物组合物。

36. 发明申请

US20080311608A1 Antagonist of the oncogenic activity of the protein MDM2, and use thereof in the treatment of cancers 审中-公开
标题翻译：蛋白质MDM2的致癌活性的拮抗剂及其在治疗癌症中的用途
公开(公告)号：US20080311608A1
公开(公告)日：2008-12-18
申请号：US11651486
申请日：2007-01-10
申请人： Bruno Tocque , Bohdan Wasylyk , Marie-Christine Dubs-Poterszman
发明人： Bruno Tocque , Bohdan Wasylyk , Marie-Christine Dubs-Poterszman
IPC分类号： C12Q1/02 , C12N5/10
CPC分类号： C07K16/40 , A61K38/00 , C07K14/4705 , C07K14/4736 , C07K14/82 , C07K16/00 , C07K16/32 , C12N15/1137 , C12N2799/021 , C12N2799/022 , C12N2799/027
摘要： The present invention relates to the utilization of a compound capable of antagonizing at least partially the oncogenic activity of the protein Mdm2 for the preparation of a pharmaceutical composition intended more particularly to a treatment of cancers with no p53 context. It further relates to the viral vector comprising a nucleic acid sequence coding for a compound capable of inhibiting at least partially the oncogenic activity of the protein Mdm2, and to a corresponding pharmaceutical composition.
摘要翻译：本发明涉及能够至少部分地拮抗蛋白质Mdm2的致癌活性的化合物用于制备药物组合物的药物组合物的用途，更具体地说是治疗无p53上下文的癌症。它还涉及包含编码能够至少部分地抑制蛋白Mdm2的致癌活性的化合物的核酸序列的病毒载体和相应的药物组合物。

37. 发明申请

US20040209834A1 Antagonists of the oncogenic activity of the MDM2, and use thereof in the treatment of cancers 审中-公开
标题翻译： MDM2的致癌活性的拮抗剂及其在治疗癌症中的用途
公开(公告)号：US20040209834A1
公开(公告)日：2004-10-21
申请号：US10724225
申请日：2003-12-01
发明人： Bruno Tocque , Bohdan Wasylyk , Marie-Christine Dubs-Poterszman
IPC分类号： C12Q001/68 , G01N033/574 , A61K048/00
CPC分类号： C07K16/40 , A61K38/00 , C07K14/4705 , C07K14/4736 , C07K14/82 , C07K16/00 , C07K16/32 , C12N15/1137 , C12N2799/021 , C12N2799/022 , C12N2799/027
摘要： The present invention relates to the utilization of a compound capable of antagonizing at least partially the oncogenic activity of the protein Mdm2 for the preparation of a pharmaceutical composition intended more particularly to a treatment of cancers with no p53 context. It further relates to the viral vector comprising a nucleic acid sequence coding for a compound capable of inhibiting at least partially the oncogenic activity of the protein Mdm2, and to a corresponding pharmaceutical composition.
摘要翻译：本发明涉及能够至少部分地拮抗蛋白质Mdm2的致癌活性的化合物用于制备药物组合物的药物组合物的用途，更具体地说是治疗无p53上下文的癌症。它还涉及包含编码能够至少部分地抑制蛋白Mdm2的致癌活性的化合物的核酸序列的病毒载体和相应的药物组合物。

38. 发明授权

US06663856B1 Method of inhibiting cancer cell growth using a vector expressing pRb2/P130 失效
标题翻译：使用表达pRb2 / P130的载体抑制癌细胞生长的方法
公开(公告)号：US06663856B1
公开(公告)日：2003-12-16
申请号：US09089194
申请日：1998-06-02
申请人： Antonio Giordano
发明人： Antonio Giordano
IPC分类号： A61K4800
CPC分类号： C07K14/4736 , A61K48/00
摘要： Methods of inhibiting growth of cancer cells and treating cancer in a patient by administration of a vector expressing pRb2/p130 are provided.
摘要翻译：提供了通过施用表达pRb2 / p130的载体抑制癌细胞生长和治疗患者癌症的方法。

39. 发明申请

US20030211598A1 Compositions and methods for therapeutic use 审中-公开
标题翻译：用于治疗用途的组合物和方法
公开(公告)号：US20030211598A1
公开(公告)日：2003-11-13
申请号：US10454662
申请日：2003-06-03
申请人： CANJI, INC.
发明人： Heidrun Engler , Bernard G. Huyghe , Daniel C. Maneval , Paul Shabram
IPC分类号： A61K048/00 , C12N015/86
CPC分类号： A61K47/186 , A61K9/0019 , A61K38/1709 , A61K47/10 , A61K48/00 , C07K14/4736 , C07K14/4746 , C12N15/87 , C12N2799/022
摘要： A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.
摘要翻译：一种用于使用基因递送系统（例如病毒载体递送系统）治疗癌症的方法和药物组合物，其包含治疗性基因如p53或成视网膜细胞瘤肿瘤抑制基因，其中所述基因递送系统配制在包含递送 - 增强剂如乙醇或洗涤剂。

40. 发明申请

US20030166230A1 Methods and compositions for modulating tumor suppression 失效
标题翻译：用于调节肿瘤抑制的方法和组合物
公开(公告)号：US20030166230A1
公开(公告)日：2003-09-04
申请号：US10107521
申请日：2002-03-25
发明人： Yoshihiro Nakatani
IPC分类号： A61K038/46 , C07H021/04 , C12N009/22 , C12P021/02 , C12N005/06
CPC分类号： C07K14/4736 , A61K38/00 , C07K14/47
摘要： The purification of native RB (retinoblastoma) as a complex, including P107, P130, and a 600 kDa subunit, termed MTAF600 (microtubule associated factor 600) is described. MTAF600 binds to RB regardless of the phosphorylation status of RB, and binds to RB without disrupting the interaction between RB and E2F. It is further shown that E2F and DP proteins co-purified with MTAF600 and RB, such that hypophosphorylated RB may gain access to E2F as a complex with MTAF600. In addition, MTAF600 binds to microtubules and plays a role in active repression of E2F-responsive genes, cell cycle arrest, and genomic stability. The sequence of MTAF600 is described herein, along with its binding properties to proteins such as RB and microtubules, and its sequence homology. Further, methods and reagents for assaying the presence of MTAF600 or mutants thereof, pharmaceutical formulations, and methods for treating disease are also described.
摘要翻译：描述了天然RB（视网膜母细胞瘤）作为复合物的纯化，包括P107，P130和称为MTAF600（微管相关因子600）的600kDa亚基。无论RB的磷酸化状态如何，MTAF600与RB结合，并结合RB而不中断RB和E2F之间的相互作用。进一步显示E2F和DP蛋白与MTAF600和RB共同纯化，使得低磷酸化的RB可以获得与MTAF600复合物的E2F的接触。此外，MTAF600与微管结合，并在E2F反应基因的活性抑制，细胞周期停滞和基因组稳定性中发挥作用。本文描述了MTAF600的序列，以及其与蛋白质如RB和微管的结合特性及其序列同源性。此外，还描述了用于测定MTAF600或其突变体的存在的方法和试剂，药物制剂和用于治疗疾病的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式